# Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

> **NCT03330405** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 223 (actual)

## Conditions studied

- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

## Interventions

- **DRUG:** Avelumab Phase 1b
- **DRUG:** Talazoparib Phase 1b
- **DRUG:** Avelumab Phase 2
- **DRUG:** Talazoparib Phase 2

## Key facts

- **NCT ID:** NCT03330405
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-19
- **Primary completion:** 2022-02-22
- **Final completion:** 2023-01-04
- **Target enrollment:** 223 (ACTUAL)
- **Why stopped:** The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03330405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03330405, "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03330405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*